# Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

> **NCT06504368** · PHASE1 · RECRUITING · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 32 (estimated)

## Conditions studied

- Solid Tumors, Adult

## Interventions

- **DRUG:** DCR-PDL1

## Key facts

- **NCT ID:** NCT06504368
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-29
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504368, "Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06504368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*